* Your assessment is very important for improving the work of artificial intelligence, which forms the content of this project
MMP Preferred Drugs - SSRIs and SNRIs As part of the Preferred Drugs initiative the Medicines Management Programme (MMP) is considering two further drug classes; selective serotonin re-uptake inhibitors (SSRIs) serotonin noradrenaline re-uptake inhibitors (SNRIs) These drug classes are being reviewed with the aim of recommending the preferred SSRI and SNRI to prescribers in the first quarter of 2014. The SSRIs being considered for inclusion in the Preferred Drugs initiative are: citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine sertraline. These drugs are used for a wide range of conditions including depression, generalised anxiety disorder, panic disorder, etc. The SNRIs for consideration are: venlafaxine duloxetine. The MMP now invite submissions from stakeholders to inform the selection process which will consider a range of criteria including licensed therapeutic indication(s), clinical outcome data, clinical guidelines, cost, patient factors and prescribing trends in Ireland. Submissions should be made to: The National Centre for Pharmacoeconomics, St. James’s Hospital, Dublin 8 or email@example.com The closing date for submissions is close of business on Wednesday 30th November, 2013.